Stockscreener 앱 받기
74.07
0.71%
0.52
시간 외 거래:
74.08
0.01
+0.01%
Astrazeneca PLC 주식(AZN)의 최신 뉴스
Revna Biosciences and AstraZeneca Increase Access to Lung Cancer Treatment in Ghana - sg.finance.yahoo.com
Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight - GlobeNewswire Inc.
Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts - Benzinga
AstraZeneca’s PROGRESS-CKD Study: A New Frontier in Hypertension and Kidney Disease Research - TipRanks
AstraZeneca’s Real-World Study on NSCLC Drugs: Key Insights for Investors - TipRanks
AstraZeneca’s Phase II Study on AZD9291: A Promising Update for NSCLC Treatment - TipRanks
AstraZeneca’s AZD9291 Trial: A New Hope for Lung Cancer Treatment? - TipRanks
AstraZeneca: Great Portfolio, But Not A Great Price (NASDAQ:AZN) - Seeking Alpha
AstraZeneca’s NeoCOAST-2 Study: A New Frontier in Lung Cancer Treatment - The Globe and Mail
AstraZeneca’s Andexanet Alfa Study: Real-World Insights for Investors - The Globe and Mail
AstraZeneca’s Real-World Study on Koselugo: Key Insights for Investors - The Globe and Mail
AstraZeneca’s Phase II Study on Olaparib in Ovarian Cancer: A Market Perspective - The Globe and Mail
AstraZeneca’s Anifrolumab Study: A Potential Game-Changer in Inflammatory Myopathies - TipRanks
AstraZeneca’s Promising Phase 2b Study on AZD2693 for NASH: Key Insights for Investors - TipRanks
AstraZeneca’s Phase III Study on Baxdrostat and Dapagliflozin: A Potential Game-Changer for CKD Treatment - TipRanks
AstraZeneca’s Latest NSCLC Study: A Potential Game-Changer? - The Globe and Mail
AstraZeneca’s Promising CAR T-Cell Therapy Study: Key Insights for Investors - TipRanks
AstraZeneca’s Phase I Study on AZD4954: A Potential Game-Changer in Cardiovascular Treatment - The Globe and Mail
AstraZeneca’s Anifrolumab Study: Real-world Insights into SLE Treatment - TipRanks
AstraZeneca’s ARTEMIDE-Lung03 Study: A New Frontier in NSCLC Treatment - TipRanks
AstraZeneca’s PANGEIA-2 Study: Unveiling New Insights in Breast Cancer Mutations - TipRanks
AstraZeneca’s TROPION-Lung05 Study: A New Hope for Advanced NSCLC - TipRanks
AstraZeneca’s New Trial: Exploring AZD8421 for Advanced Cancers - TipRanks
AstraZeneca’s Real-World Study on mCRPC Treatment: Key Insights for Investors - TipRanks
AstraZeneca’s New Study on TDC Treatment for mNSCLC: Key Insights for Investors - TipRanks
Inside AstraZeneca’s long-term strategy in lung cancer - BioPharma Dive
Swedish Shares in North America – AstraZeneca Rises 1.1 Percent - MarketScreener
AstraZeneca’s Promising Phase II Study on AZD6234: A Potential Game-Changer for Type 2 Diabetes - TipRanks
AstraZeneca’s New COPD Study: Potential Market Shifts Ahead - TipRanks
Amgen and AstraZeneca’s HORIZON Study: A New Hope for Pediatric Asthma - TipRanks
AstraZeneca’s AZD9592 Study: A New Hope for Advanced Solid Tumors - TipRanks
AstraZeneca’s New Study on AZD5004: Potential Market Implications - TipRanks
AstraZeneca’s Phase III Study on Advanced Liver Cancer: Key Insights for Investors - TipRanks
AstraZeneca’s Promising Study on Volrustomig for Mesothelioma: Key Insights for Investors - TipRanks
AstraZeneca’s TITANium Study: A New Hope for B-Cell Malignancies? - TipRanks
AstraZeneca’s New Phase III Study: A Potential Game-Changer in Lung Cancer Treatment? - TipRanks
AstraZeneca’s Phase 1 Study on AZD9833: A New Hope for Advanced Breast Cancer - TipRanks
AstraZeneca’s MaesTTRo Study: Real-world Insights into ATTR Amyloidosis - TipRanks
AstraZeneca’s New Study on Saruparib: A Potential Game-Changer in Prostate Cancer Treatment - TipRanks
AstraZeneca’s Study on ATTR PN in Russian CTS Patients: Key Insights for Investors - TipRanks
AstraZeneca’s COPD Study: Key Insights and Market Impact - TipRanks
AstraZeneca’s New Study on NSCLC Treatment Patterns: What Investors Need to Know - TipRanks
AstraZeneca’s New Study Aims to Revolutionize COPD Care - TipRanks
AstraZeneca’s New Study on Trastuzumab Deruxtecan: A Potential Game-Changer in Cancer Treatment - The Globe and Mail
AstraZeneca’s Myasthenia Gravis Study in China: Key Insights for Investors - TipRanks
AstraZeneca Advances NASH Research with New Clinical Study - TipRanks
September 26th Options Now Available For AstraZeneca (AZN) - Nasdaq
Cancer Vaccines Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon - The Globe and Mail
Inside AstraZeneca’s long-game strategy in lung cancer - PharmaVoice
Ex-dividend day weighs heavily on the FTSE this week - Proactive financial news
AstraZeneca’s Osimertinib Study: A Potential Game-Changer for NSCLC Treatment - TipRanks
AstraZeneca’s Olaparib Study: Promising Update for Ovarian Cancer Treatment - TipRanks
Collaborating to innovate: AstraZeneca's collaborations in mRNAs, antisense oligos and cell therapy - BioXconomy
AstraZeneca, Sanofi Fail to Escape Drugmaker Conspiracy Claims - Bloomberg Law News
AstraZeneca’s Ongoing Study on Ovarian Cancer: Key Insights for Investors - TipRanks
AstraZeneca’s Promising NASH Treatment Study: Key Insights for Investors - TipRanks
AstraZeneca’s New Trial: A Potential Breakthrough for Eosinophilic Diseases in Children - TipRanks
AstraZeneca’s Phase III Study: A Potential Game-Changer for CKD Treatment - TipRanks
Ex-Dividend Reminder: AstraZeneca, Charles Schwab and Brookline Bancorp - Nasdaq
ASTRAZENECA PLC To Go Ex-Dividend On August 7th, 2025 With 1.01814 USD Dividend Per Share - 富途牛牛
AUGUST 11 DEADLINE: Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
AstraZeneca’s New Phase III Trial Targets Unresectable Pleural Mesothelioma - TipRanks
AstraZeneca’s Latest Clinical Study: Evaluating AZD5004’s Impact on Drug Interactions - TipRanks
AstraZeneca’s Ongoing Study on Olaparib for Advanced Ovarian Cancer: Market Implications - TipRanks
자본화:
|
볼륨(24시간):